Improving Physical Ability and Cellular Senescence Elimination in HIV
Public ClinicalTrials.gov record NCT07144293. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Study identification
- NCT ID
- NCT07144293
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 82 participants
Conditions and interventions
Conditions
Interventions
- Dasatinib Drug
- Quercetin Drug
- Placebo - Dasatinib Other
- Placebo - Quercetin Other
Drug · Other
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 3, 2025
- Primary completion
- Aug 31, 2026
- Completion
- Aug 31, 2026
- Last update posted
- Jul 16, 2026
2025 – 2026
United States locations
- U.S. sites
- 25
- U.S. states
- 14
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Los Angeles CARE Center CRS (Site ID: 601) | Los Angeles | California | 90035-4709 | — |
| UCSD Antiviral Research Center CRS (Site ID: 701) | San Diego | California | 92103 | — |
| University of California, San Francisco HIV/AIDS CRS (Site ID: 801) | San Francisco | California | 94143 | — |
| Harbor University of California Los Angeles Center CRS (Site ID: 603) | Torrance | California | 90502 | — |
| University of Colorado Hospital CRS (Site ID: 6101) | Aurora | Colorado | 80045 | — |
| Whitman-Walker Institute, Inc. CRS (Site ID: 31791) | Washington D.C. | District of Columbia | 20009 | — |
| Northwestern University CRS (Site ID: 2701) | Chicago | Illinois | 60611 | — |
| Massachusetts General Hospital CRS (MGH CRS) (Site ID: 101) | Boston | Massachusetts | 02114 | — |
| Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS (Site ID: 107) | Boston | Massachusetts | 02115 | — |
| Washington University Therapeutics (WT) CRS (Site ID: 2101) | St Louis | Missouri | 63110-1010 | — |
| New Jersey Medical School Clinical Research Center CRS (Site ID: 31786) | Newark | New Jersey | 07103 | — |
| Weill Cornell Chelsea CRS (Site ID: 7804) | New York | New York | 10010 | — |
| Columbia Physicians & Surgeons (P&S) CRS (Site ID: 30329) | New York | New York | 10032 | — |
| Weill Cornell Uptown CRS (Site ID: 7803) | New York | New York | 10065 | — |
| University of Rochester Adult HIV Therapeutic Strategies Network CRS (Site ID: 31787) | Rochester | New York | 14642 | — |
| Chapel Hill CRS (Site ID: 3201) | Chapel Hill | North Carolina | 27599 | — |
| Greensboro CRS (Site ID: 3203) | Greensboro | North Carolina | 27401 | — |
| Cincinnati CRS (Site ID: 2401) | Cincinnati | Ohio | 45267-0405 | — |
| Case CRS (Site ID: 2501) | Cleveland | Ohio | 44106 | — |
| Ohio State University CRS (Site ID: 2301) | Columbus | Ohio | 43210 | — |
| Penn Therapeutics CRS (Site ID: 6201) | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh CRS (Site ID: 1001) | Pittsburgh | Pennsylvania | 15213 | — |
| Vanderbilt Therapeutics (VT) CRS (Site ID: 3652) | Nashville | Tennessee | 37204 | — |
| Houston Advancing Research Team CRS (Site ID: 31473) | Houston | Texas | 77030 | — |
| University of Washington Positive Research CRS (Site ID: 1401) | Seattle | Washington | 98104-9929 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07144293, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 16, 2026 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07144293 live on ClinicalTrials.gov.